The nano-based theranostics for respiratory complications of COVID-19

• Published in: Drug development and industrial pharmacy 2021-09, Vol.47 (9), p.1353-1361
• Main Authors: Ghasemzad, Mahsa, Hashemian, Seyed Mohammad Reza, Memarnejadian, Arash, Akbarzadeh, Iman, Hossein-Khannazer, Nikoo, Vosough, Massoud
• Format: Article
• Language: English
• Subjects: COVID-19; inhalable nanoparticles; Nanomedicine-based technologies; nanomedicine-based theranostics modalities; Regenerative medicine
• ISSN: 0363-9045; 1520-5762
• DOI: 10.1080/03639045.2021.1994989

High morbidity and mortality caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made coronavirus disease 2019 (COVID-19) the leading challenge for health experts all over the world. Currently, there is no specific treatment for COVID-19; however, thanks to worldwide intense attempts, novel vaccines such as mRNA-1273 (Moderna TX, Inc.) and BNT162b2 (Biontech/Pfizer) were developed very fast and FDA approved them for emergency use. Nanomedicine-based drug delivery can be an advanced therapeutic strategy to deal with clinical complications of COVID-19. Given the fact that SARS-CoV-2 typically affects the respiratory tract, application of inhalable nanoparticles (NPs) for targeted drug delivery to the alveolar space appears to be an effective and promising therapeutic strategy. Loading the medicinal components into NPs enhances the stability, bioavailability, solubility and sustained release of them. This approach can circumvent major challenges in efficient drug delivery such as solubility and any adverse impact of medicinal components due to off-targeted delivery and resulting systemic complications. Inhalable NPs could be delivered through nasal sprays, inhalers, and nebulizers. NPs also could interfere in virus attachment to host cells and prevent infection. Moreover, nanomedicine-based technologies can facilitate accurate and rapid detection of virus compared to the conventional methods. In this review, the nano-based theranostics modalities for the management of respiratory complications of COVID-19 were discussed.